To investigate the clinical implications of NEAT1 and MALAT1 regulation on A3B activity, we analysed The Cancer Genome Atlas (TCGA) datasets for breast cancer (BRCA) and lung adenocarcinoma (LUAD) [42], cancers that are known for having significant APOBEC-mediated mutational signatures and A3A/A3B aberrant overexpression [12]. The gene discussed is NEAT1; the disease is breast carcinoma.